What can patient-centred drug development look like?

In the late 1990s, pressure from HIV/AIDS campaigners famously led the AIDS Clinical Trial Group—the government body setting standards in the United States for trials—to give activists a role in the design, implementation and evaluation of trials. The activists, mostly patients, brought useful input, such as insisting that the group of trial participants more closely match the population that had the disease. This notably led to the inclusion of more ethnic minorities and women in trials.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week